Carcinoma

Researchers at University of Florence, Medical Department target carcinoma

Published in Pharma Investments, Ventures and Law Weekly, August 23rd, 2009

"Patients with peritoneal carcinomatosis (PC) of colorectal origin have a poor prognosis (median survival of 6 months). Cytoreductive surgery (CS) with intra-peritoneal chemotherapy with or without hyperthermia (HIPEC or EPIC) allows encouraging survivals rates of 22-60 months to be obtained, with an acceptable mortality and morbidity," scientists writing in the journal Hepato - Gastroenterology report.

"Nevertheless, the role of cytoreductive surgery alone is little explored in literature. The aim of this study was to better understand the role of CS alone in the treatment of PC of colorectal origin. The outcome of 27 patients with PC of colorectal origin who...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly

Source: Pharma Investments, Ventures and Law Weekly (2009-08-23)

More Articles from Pharma Investments, Ventures and Law Weekly

Alimentation COUCHE-TARD INC.
Couche-Tard Launches its New Share Repurchase Program
Alliance for Digital Equality
Partners for Digital Equality, Tutor.com, and Clayton County Government Announce Collaborative Effort: PDE Learning Without Walls LearningWOW
AmerenUE
AmerenUE Requests $140 Million in Federal Stimulus Grants to Fund Smart Grid, Advanced Management System, Electric Vehicle Projects
American Federation of Government Employees
Author of 'Why Unions Matter' to Be Featured on 'Inside Government'
American Life League
Despite Attacks, A.L.L. Calls on Catholic Organizations to Condemn 'Obamacare'
Americans for Consumer Credit Choice
Americans for Consumer Credit Choice Releases Debt Management Industry Study
More from this issue of Pharma Investments, Ventures and Law Weekly

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry